Related Experiment Video
Updated: Aug 7, 2025
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
Published on: June 16, 2023
CORRELATION BETWEEN HEPCIDIN AND PROCALCITONIN AND THEIR DIAGNOSTIC ROLE IN PATIENTS WITH COVID-19
Ghusoon Al-Janabi1, Ali Al-Fahham2, Alyaa Neamah Najm Alsaedi3
1CLINICAL LABORATORIES DEPARTMENT, APPLIED MEDICAL SCIENCES COLLEGE, KERBALA UNIVERSITY, KERBALA, IRAQ.
Insights
Serum levels of procalcitonin and hepcidin are elevated in COVID-19 patients, indicating their potential as diagnostic markers. These inflammatory markers show higher concentrations in severe cases, suggesting diagnostic utility.
Area of Science:
- Biochemistry
- Infectious Diseases
- Clinical Diagnostics
Background:
- COVID-19 is a global health crisis with significant inflammatory responses.
- Understanding biomarkers for COVID-19 diagnosis and severity is crucial.
Purpose of the Study:
- To investigate the association between procalcitonin and hepcidin in COVID-19 patients.
- To evaluate the diagnostic role of procalcitonin and hepcidin in COVID-19.
Main Methods:
- A cohort of 75 COVID-19 patients and 50 healthy controls were enrolled.
- Serum levels of procalcitonin and hepcidin were measured using electrochemiluminescent immunoassay (ECLIA).
Main Results:
- Significantly elevated serum concentrations of hepcidin and procalcitonin were observed in COVID-19 patients compared to healthy subjects.
- Hepcidin and procalcitonin levels were markedly higher in severe COVID-19 cases (p < 0.01).
- Procalcitonin and hepcidin demonstrated high diagnostic sensitivity (0.88% and 0.85%, respectively).
Conclusions:
- Serum hepcidin and procalcitonin are increased in COVID-19 patients, acting as inflammatory markers.
- These markers exhibit high sensitivity and diagnostic power for COVID-19.
- Elevated levels of hepcidin and procalcitonin are particularly evident in severe COVID-19 cases.
Objective:
The aim: The purpose of this study is to find out the association between procalcitonin and hepcidin in patients with COVID-19, in addition to their role as diagnostic markers.
Patients And Methods:
Materials and methods: A total of 75 patients infected with coronavirus were included in the current study, their age is ranging between 20 to 78 years. Those patients was hospitalized in Al-Sadr Teaching Hospital in Najaf, in Iraq. This study also included 50 healthy subjects which are volunteers and considered as a (control group). Biomarker (procalcitonin and hepcidin) measurements were achieved by electrochemiluminescent immunoassay (ECLIA) in the Elecsys immunoassay system.
Results:
Results: The present study showed a significant increase the serum cencentration of hepcidin and procalcitonin in patients with COVID-19 as compared tohealthy subjects. There was a highly significant increasing(p < 0.01) in hepcidin and PCT level in patients with severe infection comparing to other catgaries.The current study also revealed that the sensitivity values of the markers were: 0.88%, 0.85 for procalcitonin and hepcidin respectively, which indicate high diagnostic power.
Conclusion:
Conclusions: Serum levels of hepcidin and procalcitonin are increased as inflammatory markers in COVID-19 patients with relatively high sensitivity. It seems that these imflammatory markers obviously elevate in the severe cases COVID-19dusease.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Related Concept Videos
01:13Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
01:30Pneumonia III: Complications and Assessment
01:19Pericarditis II: Clinical Features and Diagnostic Tests